Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,290.54 +13.03 (+0.25%) Dow
38,648.55 -37.77 (-0.10%) Nasdaq
16,854.90 +119.88 (+0.72%) Bitcoin USD
69,812.50 +1,749.95 (+2.57%) CMC Crypto 200
1,503.46 +35.53 (+2.42%)
Zealand Pharma A/S (ZEAL.CO)
| Previous close | 639.50 |
| Open | 637.00 |
| Bid | 647.00 x 0 |
| Ask | 649.50 x 0 |
| Day's range | 627.50 - 650.00 |
| 52-week range | 212.20 - 749.00 |
| Volume | |
| Avg. volume | 307,614 |
| Market cap | 40.462B |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -12.41 |
| Earnings date | 15 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 792.38 |
GlobeNewswireZealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
Press release – No. 6 / 2024 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency Copenhagen, Denmark, May 31, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a po
- GlobeNewswire
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
Press release – No. 5 / 2024 Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024 Copenhagen, Denmark, May 29, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Adam Steensberg, President and CEO, will participate in fireside chats at the following healthcare investor conferences in June: Jefferies Global Healthcare Conference,
- GlobeNewswire
Zealand Pharma major shareholder announcement: Polar Capital
Company announcement – No. 28 / 2024 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark, 29 May 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 24 May 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: As of 22 May 2024, Pol
